Below are the most recent publications written about "Angiotensin II" by people in Profiles.
-
Wu Q, Rafatian N, Wagner KT, Blamer J, Smith J, Okhovatian S, Aggarwal P, Wang EY, Banerjee A, Zhao Y, Nash TR, Lu RXZ, Portillo-Esquivel LE, Li CY, Kuzmanov U, Mandla S, Virlee E, Landau S, Lai BF, Gramolini AO, Liu C, Fleischer S, Veres T, Vunjak-Novakovic G, Zhang B, Mossman K, Broeckel U, Radisic M. SARS-CoV-2 pathogenesis in an angiotensin II-induced heart-on-a-chip disease model and extracellular vesicle screening. Proc Natl Acad Sci U S A. 2024 Jul 09; 121(28):e2403581121.
-
Silva AF, Torres MDT, Silva LS, Alves FL, Miranda A, Oliveira VX, de la Fuente-Nunez C, Pinheiro AAS. Synthetic angiotensin II peptide derivatives confer protection against cerebral and severe non-cerebral malaria in murine models. Sci Rep. 2024 02 26; 14(1):4682.
-
Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock KM, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine N, Tiffany B, Douglas IS, Levitt J, Busse LW, Ginde AA, Brown SM, Hager DN, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall AJ, DeClercq J, Lavieri R, Joly MM, Orr M, Pulley J, Rice TW, Schildcrout JS, Semler MW, Wang L, Bernard GR, Collins SP. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA. 2023 04 11; 329(14):1170-1182.
-
Wang EY, Kuzmanov U, Smith JB, Dou W, Rafatian N, Lai BFL, Lu RXZ, Wu Q, Yazbeck J, Zhang XO, Sun Y, Gramolini A, Radisic M. An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy. J Mol Cell Cardiol. 2021 11; 160:97-110.
-
Shahini N, Schjalm C, Nilsson PH, Holt MF, ?gaard JDS, Lien E, Ahmed MS, Attramadal H, Aukrust P, Yndestad A, Mollnes TE, Louwe MC. Complement component C3 and the TLR co-receptor CD14 are not involved in angiotensin II induced cardiac remodelling. Biochem Biophys Res Commun. 2020 03 19; 523(4):867-873.
-
Giatsidis G. Discussion: Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model. Plast Reconstr Surg. 2019 11; 144(5):814e-815e.
-
Kr?ller-Sch?n S, Jansen T, Tran TLP, Kvandov? M, Kalinovic S, Oelze M, Keaney JF, Foretz M, Viollet B, Daiber A, Kossmann S, Lagrange J, Frenis K, Wenzel P, M?nzel T, Schulz E. Endothelial a1AMPK modulates angiotensin II-mediated vascular inflammation and dysfunction. Basic Res Cardiol. 2019 01 14; 114(2):8.
-
Jansen T, Kr?ller-Sch?n S, Sch?nfelder T, Foretz M, Viollet B, Daiber A, Oelze M, Brandt M, Steven S, Kvandov? M, Kalinovic S, Lagrange J, Keaney JF, M?nzel T, Wenzel P, Schulz E. a1AMPK deletion in myelomonocytic cells induces a pro-inflammatory phenotype and enhances angiotensin II-induced vascular dysfunction. Cardiovasc Res. 2018 12 01; 114(14):1883-1893.
-
Silva LS, Peruchetti DB, Silva-Aguiar RP, Abreu TP, Dal-Cheri BKA, Takiya CM, Souza MC, Henriques MG, Pinheiro AAS, Caruso-Neves C. The angiotensin II/AT1 receptor pathway mediates malaria-induced acute kidney injury. PLoS One. 2018; 13(9):e0203836.
-
Silva AF, Torres MT, Silva LS, Alves FL, de S? Pinheiro AA, Miranda A, Capurro ML, de la Fuente-Nunez C, Oliveira VX. Angiotensin II-derived constrained peptides with antiplasmodial activity and suppressed vasoconstriction. Sci Rep. 2017 10 30; 7(1):14326.